Cited by 372Glioma Diagnosis and TreatmentCancer survivorship and careOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Open access

Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L.Y., Macdonald, D., Heimans, J.J., Zonnenberg, B.A., Bravo-Marques, J.M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., Zaknoen, S.·2001·Annals of Oncology

DOI 10.1023/a:1008382516636

Open this paper in CoChat — free account

Abstract

Background Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly established chemotherapeutic regimens and the aim of treatment is palliation with improvement in the quality of life.Patients and methods We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70. One hundred twenty-eight patients were histologically confirmed with GBM or gliosarcoma (GS) by independent central review. Chemotherapy-naïve patients were treated with temozolomide 200 mg/m2/day orally for the first five days of a 28-day cycle. Patients previously treated with nitrosourea-containing adjuvant chemotherapy received 150 mg/m2/day for the first five days of a 28-day cycle. In the absence of grade 3 or 4 toxicity, patients on the 150 mg/m2 dose schedule were eligible for a 200 mg/m2 dose on the next cycle.Results The primary endpoint was six-month progression-free survival assessed with strict radiological and clinical criteria. Secondary endpoints included radiological response and Health-related Quality of Life (HQL). Progression-free survival at six months was 18% (95% confidence interval (CI): 11%-26%) for the eligible-histology population. Median progression-free survival and median overall survival were 2.1 months and 5.4 months, respectively. The six-month survival rate was 46%. The objective response rate (complete response and partial response) determined by independent central review of gadolinium-enhanced magnetic resonance imaging (MRI) scans was 8% for both the ITT and eligible-histology populations, with an additional 43% and 45% of patients, respectively, having stable disease (SD). Objectively assessed response and maintenance of a progression-free status were both associated with HQL benefits (characterized by improvements over baseline in HQL domains). Temozolomide had an acceptable safety profile, with only 9% of therapy cycles requiring a dose reduction due to thrombocytopenia. There was no evidence of cumulative hematologic toxicity.Conclusions Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM. The use of this drug should be explored further in an adjuvant setting and in combination with other agents.

Integrity signals

Registry

Crossref · 10.1023/a:1008382516636

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citation
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 2×
“We evaluated the therapeutic efficacy of single-agent temozolomide, an oral imidazotetrazine recently introduced for the management of malignant glioma at recurrence [19, 21, 22, 28, 29].”
BackgroundSelf-citation
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
Yung, W. K. A., Prados, M. D., Yayá, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R. E., Olson, J. J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 756
Self-citation
Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement
Grøenvold, M., Klee, M., Sprangers, M. A. G., & Aaronson, N. K. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00428-3 · Cited by 494
Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Christopher Kennard, C., Colquhoun, I. R., Lewis, P. D., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 275
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Beǵent, R. H. J., Calvert, H., Colquhoun, I. R., Lewis, P., & Brampton, M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050691 · Cited by 218
Self-citation
Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme
Osoba, D., Brada, M., Yung, W. K. A., & Prados, M. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1481 · Cited by 209
Self-citation
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
Brada, M., Judson, I. R., Beale, P. J., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M. H., Batra, V., & Cutler, D. L. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Self-citation
The charing cross hospital experience with temozolomide in patients with gliomas
Newlands, E. S., O'Reilly, S. M., Glaser, M. G., Bower, M., Evans, H. S., Brock, C., Brampton, M., Colquhoun, I. R., Lewis, P. D., Rice-Edwards, J. M., et al. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00258-4 · Cited by 157

Flagged first, then by citations

Show all 35 references

2 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Rodier, 1996, Fotemustine (F) and cisplatin (P) association in patients with recurrent malignant glioma, Proc ASCO, 15, A292
Brada, 1999, Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies, Br J Cancer, 81, 1022, 10.1038/sj.bjc.6690802 · DOI

Sorted by citations

Items 201–300 of 372

Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme
Groot, C. A. U., Stupp, R., & van den Bent, M. J. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.15 · Cited by 24
Self-citation
Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience
az, R. D., Jord, M. A. V., Reynés, G., Aparicio, J., Segura, N., Amador, R., Calderero, V., & n, A. S. B. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00012 · Cited by 24
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Loghin, M. E., Prados, M. D., Wen, P. Y., Junck, L., Lieberman, F. S., Fine, H. A., Fink, K., Metha, M., Kuhn, J. G., Lamborn, K. R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0874 · Cited by 24
Laser Ablation of Recurrent Malignant Gliomas
Rodriguez, A., & Tatter, S. B. (2016) · Neurosurgery · doi:10.1227/neu.0000000000001442 · Cited by 23
“TMZ has been approved for use in recurrent HGGs as well and provides improvement in quality of life in these patients.(34) In patients with recurrent HGGs, O6-methylguanine methyltransferase promoter methylation remains a prognostic marker for improved outcome after TMZ treatment.”
Background
Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma
Nam, H. J., Kim, Y. E., Moon, B.-S., Kim, H. Y., Jung, D., Choi, S., Jang, J. W., Nam, D., & Cho, H. (2021) · iScience · doi:10.1016/j.isci.2021.102238 · Cited by 24
Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma
Boiardi, A., Eoli, M., Salmaggi, A., Lamperti, E., Botturi, A., Broggi, G., Bissola, L., Finocchiaro, G., & Silvani, A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-3030-x · Cited by 23
“The drug is active; nevertheless, in most cases responses are short-lived and generally the overall survival of glioma patients remains unaffected [5,7,13].”
BackgroundResult
New approaches for temozolomide therapy: Use in newly diagnosed glioma
Stupp, R., & Newlands, E. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90067-3 · Cited by 23
Self-citation
Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma
Brandes, A. A., Franceschi, E., Gorlia, T., Wick, W., Jacobs, A. H., Baumert, B. G., van den Bent, M. J., Weller, M., & Stupp, R. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.027 · Cited by 22
Self-citation
Towards personalized therapy for patients with glioblastoma
Shirai, K., & Chakravarti, A. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.103 · Cited by 21
Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life
Stöckelmaier, L., Renovanz, M., König, J., Nickel, K., Hickmann, A., Mayer‐Steinacker, R., Nadji‐Ohl, M., Ganslandt, O., Bullinger, L., Wirtz, C. R., et al. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.02.061 · Cited by 22
Health-related quality of life and symptom research in glioblastoma multiforme patients
TAPHOORN, M. J. B., & Bottomley, A. (2005) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.5.6.763 · Cited by 22
Chemotherapy in pediatric brain tumor and the challenge of the blood–brain barrier
Reza, M. J., Podany, A. T., Κhan, P., Shaffer, C. L., Siddiqui, J. A., Baranowska‐Kortylewicz, J., Lê, J., Fletcher, C. V., Ether, S. A., & Avedissian, S. N. (2023) · Cancer Medicine · doi:10.1002/cam4.6647 · Cited by 22
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Balañá, C., Etxániz, O., Bugés, C., & Martínez‐Martí, A. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0642-9 · Cited by 21
Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer
Choong, N. W., Mauer, A. M., Hoffman, P. C., Rudin, C. M., Winegarden, J. D., Villano, J. L., Kozloff, M. F., Wade, J. L., Sciortino, D. F., Szeto, L. L., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31575-6 · Cited by 21
Efficacy of temozolomide for recurrent embryonal brain tumors in children
Wang, C., Hsu, T., Wong, T., & Chang, K. (2008) · Child s Nervous System · doi:10.1007/s00381-008-0781-7 · Cited by 21
“The efficacy of temozolomide has been evaluated in patients with relapsed malignant glioma [2, 17].”
Background
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
Wick, W., Krendyukov, A., Junge, K., Höger, T., & Fricke, H. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03320-x · Cited by 20
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens
Batich, K. A., & Sampson, J. H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.947266 · Cited by 20
“The 6-month PFS for TMZ-treated patients was 18%, and the 6-month OS was 46% [51].”
Background
Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma
Balducci, M., Diletto, B., Chiesa, S., D’Agostino, G. R., Gambacorta, M. A., Ferro, M., Colosimo, C., Maira, G., Anile, C., & Valentini, V. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-013-0506-z · Cited by 19
Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging
Soni, V. S., & Yanagihara, T. K. (2019) · Cancer Imaging · doi:10.1186/s40644-019-0259-8 · Cited by 19
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Caroli, M., Locatelli, M., Campanella, R., Motta, F., Mora, A., Prada, F. U., Borsa, S., Boneschi, F. M., Saladino, A., & Gaini, S. M. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9343-1 · Cited by 19
Temozolomide and Radiotherapy as First-Line Treatment of High-Grade Gliomas
Corsa, P., Parisi, S., Raguso, A., Troiano, M., Perrone, A., Cossa, S., Munafò, T., Piombino, M., Spagnoletti, G., & Borgia, F. (2006) · Tumori Journal · doi:10.1177/030089160609200407 · Cited by 19
Recent therapeutic advances and insights of recurrent glioblastoma multiforme
Chen, J. (2012) · Frontiers in bioscience · doi:10.2741/4130 · Cited by 18
“Several clinical trials tried to evaluate the efficacy of TMZ in recurrent GBM with both standard 5-day schedule (24-30) and dose-dense schedule and showed varied results”
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme
Gawley, M., Almond, L., Daniel, S., Lastakchi, S., Kaur, S., Detta, A., Cruickshank, G. S., Miller, C. R., Hingtgen, S., Sheets, K., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.012 · Cited by 18
Advances in malignant glioma drug discovery
Reardon, D. A., Perry, J., Brandes, A. A., Jalali, R., & Wick, W. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.584530 · Cited by 17
“Grade III -- IV thrombocytopenia is the dose-limiting toxicity of this regimen and occurs in 7 -- 17% of patients, while grade III -- IV neutropenia occurs with lower frequency [34,36,40-42].”
BackgroundMethod
Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
Yang, S.-H., Kim, M.-K., Lee, T., Lee, K., Jeun, S.-S., Park, C.-K., Kang, J.-K., Kim, M., & Hong, Y.-K. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.4.739 · Cited by 18
“Leukopenia 3 (12) 1 (4) 0 0 Thrombocytopenia 0 0 0 0 Nausea/vomiting 7 (28) 0 0 0 Hepatic 2 (8) 1 (4) 0 0 Table 3.”
Background
Emerging drugs for malignant glioma
Mason, W. P. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.81 · Cited by 18
The Outcomes of Concomitant Chemoradiotherapy Followed by Adjuvant Chemotherapy with Temozolomide for Newly Diagnosed High Grade Gliomas : The Preliminary Results of Single Center Prospective Study
Choi, J.-W., Lee, M. M., Kim, I. A., Kim, J. H., Choe, G., & Kim, C. (2008) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2008.44.4.222 · Cited by 18
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma
Palmieri, C., Brock, C. S., & Newlands, E. S. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-3577-y · Cited by 17
“It has demonstrated efficacy as first-line therapy for patients with glioblastoma multiforme (GBM) and when given concomitantly and adjuvantly with radiotherapy in newly diagnosed GBM [4,5].”
BackgroundInfluential
Fatty Acids Rich Extract From Clerodendrum volubile Suppresses Cell Migration; Abates Oxidative Stress; and Regulates Cell Cycle Progression in Glioblastoma Multiforme (U87 MG) Cells
Erukainure, O. L., Ashraf, N., Naqvi, A. S., Zaruwa, M. Z., Muhammad, A. I., Odusote, A. D., & Elemo, G. N. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00251 · Cited by 17
“…multiforme (GBM) is a malignant primary brain tumor common amongst the young kids with range of age < 13 years, characterized by high rates of proliferation, metastasis, and resistance to chemotherapy protocols (Brada et al., 2001; Puli et al., 2006; MarkiewiczŻukowska et al., 2013).”
BackgroundInfluential
A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma
Wang, Z., Yang, G., Zhang, Y., Yao, Y., & Dong, L. (2017) · Medicine · doi:10.1097/md.0000000000008444 · Cited by 18
New chemotherapy options for the treatment of malignant gliomas
Soffietti, R., Rudà, R., & Trevisan, E. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801476fd · Cited by 17
Radiothérapie des glioblastomes : de la radiobiologie à la chimiothérapie concomitante
Simon, J.-M., Toubiana, T., Lang, P., Taillibert, S., & Mazeron, J. J. (2005) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2005.07.001 · Cited by 16
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Balañá, C., Vaz, M. A., Lopez, D., Bataller, R. D. L. P., Garcia-Bueno, J. M., Molina-Garrido, M. J., Sepúlveda-Sánchez, J. M., Cano, J. M., Bugés, C., Sanz, S., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1068-3 · Cited by 16
“No complete response to temozolomide has been observed in previous studies [14, 15], so patients that begin treatment with residual disease, after only biopsy or partial resection, were expected to still have residual disease at 8 months.”
Background
Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma
Imiela, A., Surmacki, J. M., & Abramczyk, H. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128381 · Cited by 16
Distribution of cancer stem cells in two human brain gliomas
Peng, L., Fu, J., Wang, W., Hofman, F. H., Chen, T., & Chen, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9824 · Cited by 16
New developments in the treatment of malignant gliomas
Soffietti, R., Leoncini, B., & Rudà, R. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1313 · Cited by 16
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial
Li, X., Shang, X., Liu, J., Zhang, Y., Jia, X., Li, H., Wang, Y., Gao, J., Ma, X., Zhang, X. H., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68112-6 · Cited by 15
Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
Kesselheim, J. C., Norden, A. D., Wen, P. Y., & Joffe, S. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0047 · Cited by 16
A Case of Relapsing Glioblastoma Multiforme Responding to Vinorelbine
Biassoni, V., Casanova, M., Spreafico, F., Gandola, L., & Massimino, M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9176-3 · Cited by 15
Chemotherapy of anaplastic oligodendroglial tumours
Soffietti, R. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.295 · Cited by 15
“Temozolomide has been shown to be effective in treating patients with recurrent and newly diagnosed glioblastomas and anaplastic astrocytomas [61-65].”
Background
Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium
Everaert, E. G., Neyns, B., Joosens, E. J., Strauven, T., Branle, F., & Menten, J. J. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000040809.97943.c0 · Cited by 14
“5%) was lower as compared to previous reports (29–68%) [18,19,21].”
BackgroundResult
Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma
Treggiari, E., Elliott, J. W., BAINES, S. J., & Blackwood, L. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12335 · Cited by 14
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme
Aoki, T., Mizutani, T., Ishikawa, M., Sugiyama, K., & Hashimoto, N. (2003) · International Journal of Clinical Oncology · doi:10.1007/s10147-003-0339-3 · Cited by 14
“Similar results were reported in previous studies.(4,8,9)”
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study
Hargrave, D. R., Geoerger, B., Frappaz, D., Pietsch, T., Gesner, L., Cisar, L. A., Breazna, A., Dorman, A., Cruz, O., Fuster, J. L., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1098-2 · Cited by 14
Management of Epilepsy in Oncological Patients
Villanueva, V., Codina, M., & Elices, E. (2008) · The Neurologist · doi:10.1097/01.nrl.0000340791.53413.f4 · Cited by 14
“In their design, other parameters were evaluated (radiological progression or clinical improvement) that were different from improvement in seizure frequency, a secondary aspect in many cases.(84,85) The usage of temozolomide in low-grade tumors, with a greater survival but a priori less chemosensitive, has been obser…”
Background
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas
Shah, G., Silver, J. S., Rosenfeld, S. S., Gavrilovic, I. T., Abrey, L. E., & Lassman, A. B. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9408-1 · Cited by 14
Surgery, radiotherapy and temozolomide in treating high-grade gliomas
Parlato, C. (2006) · Frontiers in bioscience · doi:10.2741/1881 · Cited by 14
“Because of its favourable pharmacokinetic and pharmacodynamic properties and improved tolerability, TMZ is has been the subject of several trial for its use as chemotherapeutic agent in newlydiagnosed GBM (12-16).”
BackgroundInfluential
Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data
Chen, S., Wang, X., Diao, C., Zhu, H., Yuan, Q., Liu, J., Li, S., Gu, M., & Zhang, Y. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s305792 · Cited by 13
“Brada reported that incidences of grade 3–4 hematological and grade 3–4 non-hematological toxicity in the temozolomide monotherapy for glioblastoma were the same as 25%.(13) Chua reported a higher incidences of grade 3–4 hematological toxicity (36.”
Background
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Martín, M. G., Bruna, J., Clopes, Fort, Gil, & Martinez, M. (2009) · Cancer Management and Research · doi:10.2147/cmr.s5598 · Cited by 13
Phase II study of two-weekly temozolomide in patients with high-grade gliomas
Wong, S., Rosenthal, M. A., DOWLING, A. J., Jennens, R. R., Woods, A.-M., Ashley, D. M., & Cher, L. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.10.018 · Cited by 13
Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
Gwak, H., Yee, G. T., Park, C., Kim, J. W., Hong, Y.-K., Kang, S., Kim, J. H., Seol, H. J., Jung, T., Chang, J. H., et al. (2013) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2013.54.6.489 · Cited by 13
“One week on–one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center
Galldiks, N., Berhorn, T., Blau, T., Dunkl, V., Fink, G. R., & Schroeter, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1048-z · Cited by 13
“In comparison with historical data of phase II clinical trials in patients with recurrent glioblastoma treated with TMZ standard dose (TMZ 5/28) [22–24], we observed a higher PFS-6 (range of PFS-6, 18–24 % vs.”
Result
Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
Fujimaki, T., Ishii, H., Matsuno, A., Arai, H., & Nakagomi, T. (2007) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-5-89 · Cited by 13
“The response rate of glioblastoma (GBM) or AA to the standard TMZ protocol of 5 days in a 28-day cycle is 7–30% [1,2,7,8].”
Background
Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies
Holmberg, K. O., Borgenvik, A., Zhao, M., Giraud, G., & Swartling, F. J. (2024) · Cancers · doi:10.3390/cancers16091752 · Cited by 13
Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma
Sarıca, F. B., Çekinmez, M., Tufan, K., Şen, O., Onal, H., Mertsoylu, H., Topkan, E., Pehlivan, B., Erdogan, B., & Altınörs, M. N. (2012) · Asian Journal of Neurosurgery · doi:10.4103/1793-5482.106650 · Cited by 12
Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review
Coomans, M. B., Peeters, M. C. M., Koekkoek, J. A. F., Schoones, J. W., Reijneveld, J. C., TAPHOORN, M. J. B., & Dirven, L. (2020) · Cancers · doi:10.3390/cancers12123502 · Cited by 12
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas
Blakeley, J. O., Grossman, S. A., Mikkelsen, T., Rosenfeld, M. R., Peereboom, D. M., Nabors, B., Chi, A. S., Emmons, G., Ribas, I. G., Supko, J. G., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1876-0 · Cited by 12
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution
Joo, J., Kim, H., Kim, Y., Han, J. H., & Kim, C. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.11.1597 · Cited by 12
“Bevacizumab (± Irinotecan) 17 (28) PCV 13 (21) Re-operation 12 (20) Gamma knife radiosurgery 8 (13) ACNU/CDDP 7 (12) Re-radiation 3 (5) Metronomic temozolomide 3 (5) Temozolomide re-trial 2 (3) Irinotecan only 1 (1.”
BackgroundInfluential
Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma
Hartmann, P., Herholz, K., Salzberger, B., & Petereit, H.-F. (2004) · Annals of Hematology · doi:10.1007/s00277-003-0802-2 · Cited by 12
“Recent studies in relapsing patients with malignant glioma confirmed these findings with 6-month survival rates of 46 and 75%, respectively [7, 50].”
Background
Complete Response of Multiple Melanoma Brain Metastases after Treatment with Temozolomide
Dvořák, J., Melichar, B., Žižka, J., Hadzi-Nikolov, D., & Petera, J. (2004) · Oncology Research and Treatment · doi:10.1159/000076908 · Cited by 12
Neuro-oncology clinical trials: Promise and pitfalls
GILBERT, M. R. (2001) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a000239 · Cited by 12
Distinct spatial N‐glycan profiles reveal glioblastoma‐specific signatures
Angerstein, A. O., Young, L. E. A., Thanasupawat, T., Vriend, J. P., Grimsley, G., Lun, X., Senger, D. L., Sinha, N., Beiko, J., Pitz, M. W., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6401 · Cited by 11
Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study
Johnston, A., Creighton, N., Parkinson, J., Koh, E.-S., Wheeler, H., Hovey, E. J., Rodriguez, M. J., & Currow, D. C. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz021 · Cited by 11
Synthesis, characterization, DNA interactions and antiproliferative activity on glioblastoma of iminopyridine platinum(II) chelate complexes
Posadas, I., Alonso‐Moreno, C., Bravo, I., Carrillo‐Hermosilla, F., Garzón‐Ruiz, A., Villaseca-González, N., López-Solera, I., Albaladejo, J., & Ceña, V. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.11.032 · Cited by 11
Perillyl alcohol as a treatment for cancer: A systematic review
Durço, A. O., Conceição, L. S. R., Souza, D. S., Lima, C. A., Quintans, J. D. S. S., & dos Santos, M. R. V. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100090 · Cited by 12
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Garcia-Martin, M., Bruna, J., Clopes, A., Fort, Gil, & Martı́nez, M. E. (2009) · Cancer Management and Research · doi:10.2147/cmar.s5598 · Cited by 11
Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients
Yang, D., Bu, X., Zhou, Z.-L., Yan, Z., Ma, C., Qu, M., Zhao, Y.-W., Kong, L., Wang, Y.-W., & Luo, J.-C. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_844_17 · Cited by 11
Malignant Gliomas in Adults
Norden, A. D., Drappatz, J., & Wen, P. Y. (2010) · Blue books of neurology · doi:10.1016/b978-0-7506-7516-1.00005-0 · Cited by 12
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction
Tanaka, S. A., Akimoto, J., Kobayashi, I., Oka, H., & Ujiié, H. (2008) · Oncology Reports · doi:10.3892/or.20.1.165 · Cited by 9
“TMZ is an oral medication with much fewer side effects than conventional anticancer agents and is thought to be extremely useful during maintenance therapy for glioma and recurrence (36,37).”
Background
Changing boundaries in the treatment of malignant gliomas
Brandes, A. A., Basso, U., & Pasetto, L. M. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.3.357 · Cited by 10
Insights into pharmacotherapy of malignant glioma in adults
Salvati, M., D’Elia, A., Formichella, A. I., & Frati, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903146910 · Cited by 9
“TMZ was initially administered in a 5-day repeated scheme and demonstrated modest activity as a single agent against recurrent GBM after standard surgical and radiotherapy treatment, with response rates of 5% and progression-free survival at 6 months (PFS6) of 21% [10-11].”
Method
Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas
Heo, J., Kim, S. H., Oh, Y., Chun, M., & Noh, O. K. (2017) · Neoplasma · doi:10.4149/neo_2017_520 · Cited by 9
Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
Joo, J., Chang, J. H., Kim, J. H., Hong, Y.-K., Kim, Y., & Kim, C. (2012) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2012.52.2.92 · Cited by 9
“D.(1) Department of Neurosurgery,1 Seoul National University Bundang Hospital, Seongnam, Korea Department of Neurosurgery,2 Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Department of Neurosurgery,3 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Neuro…”
Background
Cytostatic and cytotoxic drugs
Murphy, F., & Middleton, M. R. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00045-3 · Cited by 8
Evaluation of cognitive functions and quality of life
TAPHOORN, M. J. B., & Klein, M. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00014-1 · Cited by 8
Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression
Li, L., Du, Y., Xiang, D., Chen, L., Shi, Z., Tian, J., & Chen, X. (2018) · Biomedical Optics Express · doi:10.1364/boe.9.003193 · Cited by 8
CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas
Garcia-Vega, Y., Salva-Camaño, S., García-Iglesias, E., Cubero-Rego, D., González-Gonzalez, J., & Rivero, I. B. (2015) · Journal of Cancer Research & Therapy · doi:10.14312/2052-4994.2015-20 · Cited by 8
Survival of Patients with Recurrent???Malignant Glioma Treated???with Temozolomide
Trippoli, S., Pelagotti, F., Messori, A., Vacca, F., Vaiani, M., & Maltoni, S. (2003) · Drugs in R&D · doi:10.2165/00126839-200304050-00002 · Cited by 8
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
van den Bent, M. J., Chinot, O. L., & Cairncross, J. G. (2003) · Neuro-Oncology · doi:10.1215/s1522851702000285 · Cited by 8
NICE verdict on Temozolomide: where next?
Brada, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600134 · Cited by 8
“Following three preregistration studies which were the largest ever performed in patients with recurrent malignant glioma (Yung et al, 1999, 2000; Brada et al, 2001) it became available in clinical practice.”
MethodSelf-citation
Orphan drugs in glioblastoma multiforme: a review
Lassen, U., Mau-Soerensen, M., & Poulsen, H. S. (2014) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s46018 · Cited by 7
“The early Phase II studies in recurrent GBM defined the standard regimen as 200 mg/m(2) for 5 days every 28 days, with a response rate of 8% and PFS6 of 18%.(36) Temozolomide was granted FDA approval for the treatment of recurrent anaplastic astrocytoma in 1999, and later for recurrent GBM.”
Glioblastoma multiforme: advances in postsurgical management
Mohin, G., Madajewicz, S., Manzione, J. V., & Franceschi, D. (2006) · Community Oncology · doi:10.1016/s1548-5315(11)70921-4 · Cited by 7
Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
Gool, S. V., & Vleeschouwer, S. D. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.107 · Cited by 7
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia
Mabasa, V. H., & Taylor, S. C. M. (2006) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155206069161 · Cited by 7
Challenges of rehabilitation for patients with primary malignant glioma – a review of recent literature
Hojan, K. (2016) · Journal of Medical Science · doi:10.20883/jms.2016.91 · Cited by 7
Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study
Hassler, M. R., Micksche, M., Stockhammer, G., Pichler, J., Payer, F., Abuja, B., Deinsberger, R., & Marosi, C. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0576-3 · Cited by 7
“This compares favorably with data from other recent studies [20, 26] (Table 3) and might be due to selection of patients with favorable prognostic profiles to this study.”
Result
Drug or Vaccine?
Dai, X., Jiang, W., Wang, W., & Shu-jin, Z. (2010) · Drugs · doi:10.2165/11538040-000000000-00000 · Cited by 7
Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
Ziobro, M., Rolski, J., Grela-Wojewoda, A., Zygulska, A. L., & Niemiec, M. (2008) · PubMed · Cited by 7
Neurocytological Advances in the Treatment of Glioblastoma Multiforme
Fiani, B., Covarrubias, C., Onyedimma, C., & Jarrah, R. M. (2021) · Cureus · doi:10.7759/cureus.16301 · Cited by 6
“The results of this trial were modest yet showed certain quality improvement in the lives of patients and a favorable safety profile [30].”
BackgroundResultInfluential
Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery
Adekeye, A., Needham, D., & Rahman, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020599 · Cited by 8
Evolution of care for patients with relapsed glioblastoma
Balañá, C., Villà, S., & Teixidor, P. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.152 · Cited by 6
The Effect of Sequential Radiochemotherapy in Preirradiated Malignant Gliomas in a Phase II Study
Schäfer, U., Micke, O., Schüller, P., Schuck, A., & Willich, N. A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021898.31923.bd · Cited by 6
The Use of Temozolomide for Chemoradiation and Adjuvant Therapy of High-Grade Gliomas
Miller, J. J., & Reardon, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00031-0 · Cited by 5
Advances in the therapy of high-grade glioma at relapse: pegylated liposomal doxorubicin
Hau, P., Dietrich, J., Fabel, K. S., & Bogdahn, U. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.5.609 · Cited by 5
Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future
Cavaliere, R., & Newton, H. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.749 · Cited by 5
“It has been estimated that 6-month progression-free and overall survival were ∼ 19 and 60%, respectively, with a median time to progression and overall survival of 10 weeks and 7 months, respectively [20-22].”
Background
The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials
Franceschi, E., & Brandes, A. A. (2015) · CNS Oncology · doi:10.2217/cns.15.7 · Cited by 5
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma
Yang, P., Zhang, C., Cai, J., You, G., Wang, Y., Qiu, X., Li, S., Wu, C., Yao, K., Li, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11756 · Cited by 4
“However, the effective response of glioblastomas ranged between 5% and 8%.[18, 19] The role of TMZ chemotherapy was undefined [20] until the EORTC 26981 trial was published.”
Background
Chemotherapy for Glioblastoma: Past, Present, and Future
Giglio, P. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_10 · Cited by 4
The economics of temozolomide in brain cancer
Crott, R. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.12.1923 · Cited by 4
Supratentorial High-Grade Gliomas
Tarapore, P. E., Banerjee, A., & Gupta, N. M. (2010) · Springer eBooks · doi:10.1007/978-3-642-02874-8_26 · Cited by 4

Authors: Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., & Zaknoen, S.
Affiliations: Royal Marsden Hospital (GB)
Beatson West of Scotland Cancer Centre (GB)
University Hospital of Geneva (CH)
KU Leuven (BE)
University Medical Center Utrecht (NL)
Instituto Português de Oncologia Francisco Gentil (PT)
University Hospital of Umeå (SE)
Johns Hopkins University (US)
The University of Texas MD Anderson Cancer Center (US)
ORCID: Dietrich, P.-Y.
Dirix, L.Y.
Macdonald, D.
Heimans, J.J.
Zonnenberg, B.A.
Henriksson, R.
Stupp, R.
Rao, S.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2001-02
Volume: 12
Issue: 2
Pages: 259-266
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1023/a:1008382516636
OpenAlex: W2125643269
Cited by: 372
References: 35
Citations by year: 2026: 3 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 7 · 2020: 9 · 2019: 4 · 2018: 10 · 2017: 12 · 2016: 15 · 2015: 14 · 2014: 12 · 2013: 11 · 2012: 17
FWCI: 10.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6900 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
reroDoc Digital Library (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: University of California, San Francisco
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: temozolomide, recurrent glioblastoma, first relapse, gliosarcoma, progression-free survival, objective response rate, health-related quality of life, thrombocytopenia, chemotherapy toxicity, dose escalation, palliative care, overall survival, Karnofsky performance status
MeSH terms: Temozolomide, Adult, Aged, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Quality of Life, Disease-Free Survival, Antineoplastic Agents, Alkylating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks